Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
| ▸ | CD38 | P28907 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729416 | 1.00 | CNR2 (0.37) | CNR2CNR1TYK2CD38EPHX2 | |
| SCHEMBL22755013 | 0.84 | CD38 (0.34) | CNR2CNR1TYK2CD38KDM4E | |
| SCHEMBL22729454 | 0.83 | MAPK14 (0.39) | CNR2CNR1KDM4EHTT | |
| SCHEMBL29839293 | 0.83 | MAPK14 (0.39) | CNR2CNR1KDM4EHTT | |
| SCHEMBL22729453 | 0.83 | MAPK14 (0.39) | CNR2CNR1KDM4EHTT | |
| SCHEMBL22755193 | 0.81 | NPC1 (0.47) | CNR2CNR1KDM4E | |
| SCHEMBL19555168 | 0.75 | TYK2 (0.44) | CNR2CNR1TYK2EPHX2 | |
| SCHEMBL19555169 | 0.75 | TYK2 (0.44) | CNR2CNR1TYK2EPHX2 | |
| SCHEMBL23996089 | 0.73 | TYK2 (0.42) | CNR2CNR1TYK2EPHX2IRAK4 | |
| SCHEMBL22729860 | 0.73 | CNR2 (0.40) | CNR2CNR1CD38EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | CNR2 801/4885CNR1 856/4885TYK2 4658/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | CNR2 804/4885CNR1 851/4885TYK2 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.